Associated Papers
Impact of cancer therapy on clonal hematopoiesis mutations and subsequent clinical outcomes.
Nead KT et al.
Blood Advances, 2024
38830141 (PubMed )
Supplement: BLOODA_ADV-2024-012929-mmc1.xlsx › STable_2
Identification of Clonal Hematopoiesis Driver Mutations through In Silico Saturation Mutagenesis.
Demajo S et al.
Cancer Discovery, 2024
38722595 (PubMed )
Supplement: cd-23-1416_supplementary_table_s3_suppst3.xlsx › Supplemental_table_drivers
ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia.
Schönfeld L et al.
Leukemia, 2022
35902731 (PubMed )
Supplement: 41375_2022_1648_MOESM1_ESM.xlsx › Clinical_data
Association of clonal hematopoiesis with chronic obstructive pulmonary disease.
Miller PG et al.
Blood, 2022
34855941 (PubMed )
Supplement: 10.1182-2021013531_bloodbld2021013531-suppl1.pdf
The Dawn of next generation DNA sequencing in myelodysplastic syndromes- experience from Pakistan.
Anwar N et al.
Bmc Genomics, 2021
A de novo Variant of ASXL1 Is Associated With an Atypical Phenotype of Bohring-Opitz Syndrome: Case Report and Literature Review.
Zhao W et al.
Frontiers in Pediatrics, 2021
Genomic Analysis of Korean Patient With Microcephaly.
Lee J et al.
Frontiers in Genetics, 2020
Implications of mutational spectrum in myelodysplastic syndromes based on targeted next-generation sequencing.
Xu Y et al.
Oncotarget, 2017
29137279 (PubMed )
Supplement: oncotarget-08-82475-s003.xls › Sheet1
Germline variation in cancer-susceptibility genes in a healthy, ancestrally diverse cohort: implications for individual genome sequencing.
Bodian DL et al.
Plos One, 2014
24728327 (PubMed )
Supplement: pone.0094554.s002.xlsx › Table_S1
TET2, ASXL1 and EZH2 mutations in Chinese with myelodysplastic syndromes.
Wang J et al.
Leukemia Research, 2013
Select a paper to view details